News from pfenex inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 27, 2015, 08:00 ET
Pfenex logo

Pfenex to Present at CALBIO 2015

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced...

Feb 13, 2015, 08:30 ET
Pfenex logo

Pfenex to Present at the 2015 RBC Capital Markets' Healthcare Conference

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it...

Feb 10, 2015, 09:15 ET

Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc.,...

Jan 29, 2015, 08:00 ET
Pfenex logo

Pfenex to Present at the 17th Annual BIO CEO and Investor Conference

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced...

Dec 22, 2014, 08:30 ET
Pfenex logo

Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L

 Pfenex Inc. (NYSE MKT: PFNX) today announced the IND for Px563L, Pfenex's recombinant anthrax vaccine, has been filed and is now open and that...

Nov 13, 2014, 16:05 ET
Pfenex logo.

Pfenex Reports Third Quarter 2014 Results and Provides Business Update

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and...

Nov 06, 2014, 08:30 ET
Pfenex logo

Pfenex To Report Third Quarter 2014 Results and Provide Business Update on Thursday, November 13, 2014

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and...

Oct 09, 2014, 17:00 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex and PATH Partner on Vaccines

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value biosimilar therapeutics and...

Oct 02, 2014, 08:00 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex Added to Both Russell Microcap® Index and Russell Global Indexes

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced...

Oct 01, 2014, 16:05 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex to Present at 13th Annual BIO Investor Forum

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins...

Sep 25, 2014, 08:00 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex Adds New Board Member

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture...

Sep 19, 2014, 08:30 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex to Present at Upcoming Industry Conference on September 26

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins...

Aug 29, 2014, 16:05 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex Reports Second Quarter 2014 Results and Provides Business Update

 Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture...

Jul 29, 2014, 16:10 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex Announces Closing of Initial Public Offering

Pfenex Inc. (NYSE MKT: PFNX) today announced that it has closed its previously announced initial public offering of 8,333,333 shares of its common...

Jul 24, 2014, 00:25 ET
Pfenex logo (PRNewsFoto/Pfenex)

Pfenex Inc. Announces Pricing Of Initial Public Offering

Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing of its initial public offering of 8,333,333 shares of its common stock at a price to the...

Jun 06, 2014, 08:30 ET

Pfenex Files Registration Statement With SEC For An Initial Public Offering

 Pfenex Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial...

Dec 17, 2013, 09:05 ET

Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine

Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract in support of the development...

Nov 05, 2013, 09:00 ET

Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine

Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of...

Oct 29, 2013, 09:00 ET

Pfenex Inc. awarded a subcontract by Leidos to develop a scalable cGMP production process for a second key malaria antigen

 Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract to develop a robust,...

Oct 01, 2013, 09:00 ET